Prostate cancer is one of the most diagnosed cancers in African men and was the leading cancer for men in 40 Sub-Saharan African countries in 2020. In Southern Africa mortality is 2.7 times the global average, a disparity that reflects limited access to healthcare, inadequate early-detection programmes and underlying genetic risk factors.
Low public knowledge means many men are diagnosed too late; late-stage presentation is common in Nigeria and elsewhere, which worsens outcomes. Barriers to testing include misinformation and stigma, with some men believing screening is invasive. A man diagnosed in late 2022 reported that a routine annual check revealed the screening was a simple blood test and that early detection improved his prognosis. Health advocates stress clear messaging to increase participation.
New research by the Men of African Descent and Carcinoma of the Prostate Consortium (MADCaP) strengthens the link between African ancestry and higher, sometimes more aggressive, prostate cancer risk. Key study facts:
- Nearly 8,000 participants
- Five African countries
- Three genetic regions linked to higher risk
- Published in Nature Genetics in October
Carl Chen, a lead MADCaP researcher, said: "By focusing on African populations, we uncovered critical genetic risk factors previously unidentified." Researchers argue that data specific to African genetics can guide screening protocols and improve survival. They call for local investment in facilities and training so African scientists lead research on conditions affecting African populations.
Difficult words
- mortality — number of deaths in a population
- disparity — large and unfair difference between groups
- early-detection programme — planned set of actions to find disease earlyearly-detection programmes
- stigma — negative social attitude that harms people
- prognosis — expected course and outcome of an illness
- ancestry — family origins or ethnic background
- consortium — group of organisations working together on research
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- What actions could public health campaigns take to reduce misinformation and stigma about prostate screening in African communities?
- How might research focused on African genetics change screening or treatment for prostate cancer?
- Why is local investment in facilities and training important for research and patient outcomes in Africa?
Related articles
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.
Virtual diet and exercise program helps people with lymphoma
A study tested a virtual diet and exercise program for people getting chemotherapy for lymphoma. The program improved symptoms, attendance was high, and participants had better strength and physical performance during treatment.